Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

被引:10
|
作者
Samson, Rohan [1 ]
Le Jemtel, Thierry H. [1 ]
机构
[1] Tulane Univ, Sch Med, John W Deming Dept Med, Cardiol Sect, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源
关键词
coronary microvascular dysfunction; HFpEF; left ventricular remodeling; systemic inflammation; LEFT-VENTRICULAR HYPERTROPHY; CORONARY MICROVASCULAR DYSFUNCTION; INCIDENT CARDIOVASCULAR-DISEASE; C-REACTIVE PROTEIN; CONVERTING-ENZYME-INHIBITOR; LIPID-LOWERING TREATMENT; METABOLIC RISK-FACTORS; BODY-FAT DISTRIBUTION; ADIPOSE-TISSUE; BLOOD-PRESSURE;
D O I
10.1161/JAHA.121.021120
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection. Left ventricular remodeling promotes the development and progression of heart failure with preserved and reduced ejection fraction. However, different stimuli mediate left ventricular remodeling that is commonly concentric in heart failure with preserved ejection fraction and eccentric in heart failure with reduced ejection. The stimuli that promote concentric left ventricular remodeling may account for the neutral findings of neuhormonal modulation in heart failure with preserved ejection fraction. Low-grade systemic inflammation-induced microvascular endothelial dysfunction is currently the leading hypothesis behind the development and progression of heart failure with preserved ejection fraction. The hypothesis provided the rationale for several randomized controlled trials that have led to neutral findings. The trials and their limitations are reviewed.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Heart failure with preserved ejection fraction
    Marzia Rigolli
    Gillian A Whalley
    Journal of Geriatric Cardiology, 2013, (04) : 369 - 376
  • [32] Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma
    Bhuiyan T.
    Maurer M.S.
    Current Cardiovascular Risk Reports, 2011, 5 (5) : 440 - 449
  • [33] Diagnostic and therapeutic implications of obesity in heart failure with preserved ejection fraction
    Saito, Yuki
    Obokata, Masaru
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (01) : 190 - 192
  • [34] POLYPHARMACY, MULTIMORBIDITY, AND THERAPEUTIC COMPETITION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Brinker, Lina M.
    McNamara, Jennifer L.
    Konerman, Matthew
    Willer, Cristen J.
    Hummel, Scott
    Goyal, Parag
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1020 - 1020
  • [35] Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction?
    Menet, Aymeric
    Greffe, Lorraine
    Ennezat, Pierre-Vladimir
    Delelis, Francois
    Guyomar, Yves
    Castel, Anne Laure
    Guiot, Aurelie
    Graux, Pierre
    Tribouilloy, Christophe
    Marechaux, Sylvestre
    AMERICAN HEART JOURNAL, 2014, 168 (06) : 909 - +
  • [36] Statins Beneficial for Heart Failure With Preserved Ejection Fraction But Not Heart Failure With Reduced Ejection Fraction?
    Ohte, Nobuyuki
    Little, William C.
    CIRCULATION JOURNAL, 2015, 79 (03) : 508 - 509
  • [37] Heart failure with preserved ejection fraction: Is this diastolic heart failure?
    Zile, MR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) : 1519 - 1522
  • [38] Is heart failure with midrange ejection fraction similar to preserved ejection fraction? For
    Babkowski, M. Camafort
    REVISTA CLINICA ESPANOLA, 2017, 217 (05): : 296 - 298
  • [39] Heart failure with preserved ejection fraction (diastolic heart failure)
    Güder G.
    Ertl G.
    MMW - Fortschritte der Medizin, 2019, 161 (9) : 58 - 65
  • [40] Heart Rate in Preserved Ejection Fraction Heart Failure
    Bristow, Michael R.
    Altman, Natasha L.
    JACC-HEART FAILURE, 2017, 5 (11) : 792 - 794